The major pharmaceutical company Eli Lilly has just demonstrated efficacy of their Alzheimer’s drug donanemab in phase 2 clinical human trials. The results are a major development for the treatment of a disease that currently affects six million Americans, but that has almost no methods of alleviation. Alzheimer’s is caused by the buildup of tau […]
The post New Alzheimer’s Treatment Shows Real Promise in Slowing Cognition Decline Using Antibody in Human Trials appeared first on Good News Network.
from Good News Network https://ift.tt/2Mp4guQ
via IFTTT
No comments:
Post a Comment